Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Literature DB >> 9333073

Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Abstract

The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.

Entities: Chemical Gene

Mesh：

Substances：

Year: 1997 PMID： 9333073 PMCID： PMC164118

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors: A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal: J Clin Microbiol Date: 1992-12 Impact factor: 5.948

2. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.

Authors: E M Johnson; K G Davey; A Szekely; D W Warnock
Journal: J Antimicrob Chemother Date: 1995-11 Impact factor: 5.790

Review 3. Can we prevent azole resistance in fungi?

Authors: D W Denning
Journal: Lancet Date: 1995-08-19 Impact factor: 79.321

4. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors: J N Galgiani; M L Lewis
Journal: Antimicrob Agents Chemother Date: 1997-01 Impact factor: 5.191

5. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Authors: M A Pfaller; S Messer; R N Jones
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

6. High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

Authors: D Law; C B Moore; H M Wardle; L A Ganguli; M G Keaney; D W Denning
Journal: J Antimicrob Chemother Date: 1994-11 Impact factor: 5.790

7. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Authors: J R Perfect; G M Cox; R K Dodge; W A Schell
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

8. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Authors: E M Johnson; D W Warnock; J Luker; S R Porter; C Scully
Journal: J Antimicrob Chemother Date: 1995-01 Impact factor: 5.790

9. Improved medium for fluconazole susceptibility testing of Candida albicans.

Authors: J L Rodriguez-Tudela; J V Martinez-Suarez
Journal: Antimicrob Agents Chemother Date: 1994-01 Impact factor: 5.191

10. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Authors: J V Martinez-Suarez; J L Rodriguez-Tudela
Journal: Antimicrob Agents Chemother Date: 1995-07 Impact factor: 5.191

13 in total

Review 1. Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.

Authors: Tiene G M Bauters; Franky M A Buyle; Renaat Peleman; Hugo Robays
Journal: Pharm World Sci Date: 2005-02

2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors: F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

3. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors: A Espinel-Ingroff
Journal: J Clin Microbiol Date: 1998-10 Impact factor: 5.948

4. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors: A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

5. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors: R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

6. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.

Authors: J Molina; O Martins-Filho; Z Brener; A J Romanha; D Loebenberg; J A Urbina
Journal: Antimicrob Agents Chemother Date: 2000-01 Impact factor: 5.191